Spark Therapeutics (ONCE) Reports Q1 Loss of $1.70/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress
May 9, 2017 7:30 AM EDTWork on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete
Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported; continuing enrollment targeting participants at earlier stage of disease
PHILADELPHIA, May 09, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced financial results for the first quarter of 2017 and recent business progress.
Im pleased to announce that our work on the rolling BLA for voretigene neparvovec for... More
